deltatrials
Not Yet Recruiting PHASE2 INTERVENTIONAL 2-arm NCT07058025

Mesenchymal Stromal Cell Therapy to Prevent Bronchopulmonary Dysplasia in Extreme Preterm Infants (HULC-2)

Mesenchymal Stromal Cells in Extreme Preterm Infants at Risk of Developing Bronchopulmonary Dysplasia - A Phase 2 Multi-Centre Double Blind Randomized Controlled Trial

Sponsor: Canadian Institutes of Health Research (CIHR)

Conditions Bronchopulmonary Dysplasia (BPD) ELGAN (22-28SA)
Interventions Human Allogenic Umbilical Cord Mesenchymal Stromal Cells Sham procedure control
Updated 2 times since 2025 Last updated: Jul 8, 2025 Started: Oct 1, 2025 Primary completion: Sep 30, 2028 Completion: Sep 30, 2038
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Bronchopulmonary Dysplasia (BPD) and ELGAN (22-28SA) and is currently actively recruiting participants. Canadian Institutes of Health Research (CIHR) leads this study, which shows 2 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshotNot Yet Recruiting

Change History

2 versions recorded

  1. Sep 2025 — Present [monthly]

    Not Yet Recruiting PHASE2

  2. Aug 2025 — Sep 2025 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Canadian Institutes of Health Research (CIHR)
  • Ottawa Hospital Research Institute
  • Stem Cell Network
Data source: Ottawa Hospital Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations